Top Markets
Coin of the day
Pharvaris N.V. Pharvaris N.V.

Pharvaris N.V.

PHVS
Rankning i aktier #5575
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Aktiekurs
$36.98
Senast synkroniserad: 2026-08-26
Marknadsvärde
$2.58B
Förändring (1 dag)
-0.67%
Förändring (1 år)
55.51%
Land
NL
Handel Pharvaris N.V. (PHVS)

Kategori

Aktiekurshistorik för Pharvaris N.V. (PHVS)
Högsta slutkurs: $35.74 den 2026-08-01

Lägsta slutkurs: $31.41 den 2021-02-01
Aktiekurshistorik för Pharvaris N.V. från 2021 till 2026
Årlig aktiekursutveckling
År Prestanda
2026 (TTM) 9.05%
2025 33.94%
2024 -24.64%
2023 230.41%
2022 -49.99%
2021 0.00%
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$763.43 6.94%
CH